Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03866460 · ClinicalTrials.gov registry record
Determining Whether Intra-Arterial Carboplatin Causes Hearing Loss in Children
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 30
- Enrollment target
NCT03866460: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03866460 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03866460 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to find out how often hearing loss occurs in patients with retinoblastoma after receiving treatment with intra-arterial carboplatin.
Primary Outcome
will be defined as a \>10 db loss from baseline in any frequency, based on the lower threshold of the American Speech and Hearing Associations (ASHA) hearing change criteria. For children unable to cooperate for an audiogram, the DPOAE will be the primary measurement.
Interventions
- DIAGNOSTIC_TEST Distortion product otoacoustic emission measurement (DPOAE)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-03-06 |
| Est. Completion | 2024-11-04 |
What the finished NCT03866460 record still lists
NCT03866460 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Distortion product otoacoustic emission measurement (DPOAE) is the first listed.
NCT03866460 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03866460 about?
NCT03866460 is a clinical study titled "Determining Whether Intra-Arterial Carboplatin Causes Hearing Loss in Children". The purpose of this study is to find out how often hearing loss occurs in patients with retinoblastoma after receiving treatment with intra-arterial carboplatin.
What is the current status of trial NCT03866460?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2019-03-06. Estimated completion is 2024-11-04.
What interventions are being tested in trial NCT03866460?
The interventions under investigation include: Distortion product otoacoustic emission measurement (DPOAE) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03866460?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI